Brent Graham
Wolfson Foundation(GB)GW Pharmaceuticals (United Kingdom)(GB)
Publications by Year
Research Areas
Computational Drug Discovery Methods, Heat shock proteins research, Fibroblast Growth Factor Research, Melanoma and MAPK Pathways, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → Discovery of (2,4-Dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design(2010)261 cited
- → Fragment-Based Drug Discovery Applied to Hsp90. Discovery of Two Lead Series with High Ligand Efficiency(2010)185 cited
- → Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function(2012)112 cited
- → A Structural Comparison of Inhibitor Binding to PKB, PKA and PKA-PKB Chimera(2007)89 cited
- → The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non‐small cell lung cancer(2011)80 cited
- → Fragment-Based Discovery of a Potent, Orally Bioavailable Inhibitor That Modulates the Phosphorylation and Catalytic Activity of ERK1/2(2018)65 cited
- → Identification of spliced baculovirus RNAs expressed late in infection(1991)56 cited
- → AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders(2010)55 cited
- → Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle(2015)41 cited
- → Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models(2011)32 cited